Drugs / ABBV-903
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06078202 | Dec 2024 → Jan 2025 | — | AbbVie | Withdrawn | No outcome recorded Stop: Business |
| Phase 1 | NCT06009237 | Aug → Oct 2023 | — | AbbVie | Terminated | No outcome recorded Stop: Business |
| Phase 1 | NCT05995366 | Aug → Oct 2023 | — | AbbVie | Completed | No outcome recorded |
| Phase 1 | NCT05895266 | Jun → Nov 2023 | — | AbbVie | Completed | No outcome recorded |
| Phase 1 | NCT05836506 | Apr → Jun 2023 | — | AbbVie | Completed | No outcome recorded |
| Phase 1 | NCT05691699 | Jan → Oct 2023 | — | AbbVie | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ABBV-903 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05836506 ↗ |
| Route | Oral | “Capsule; oral” NCT05691699 ↗ |